AACR 2009: Preclinical Analysis of Combined PI3K and MEK Inhibition as a Strategy for the Treatment of Cancer

Bookmark and Share
Published: 30 Apr 2009
Views: 16191
Rating:
Save
Dr Lori Friedman - Director, Cancer Signalling and Translational Oncology, Genentech
Lori S. Friedman, Ph.D., director, Cancer Signaling and Translational Oncology, Genentech gives a presentation at the 2009 AACR meeting in Denver on: Preclinical Analysis of Combined PI3K and MEK Inhibition as a Strategy for the Treatment of Cancer.